Your session is about to expire
← Back to Search
Immunosuppressant
Nefecon for IgA Nephropathy (Nefigard Trial)
Phase 3
Waitlist Available
Research Sponsored by Calliditas Therapeutics AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Summary
This trial tests Nefecon, a daily oral medication, for patients with primary IgAN who are not improving with standard treatments. The drug aims to reduce kidney inflammation and prevent further damage.
Eligible Conditions
- IgA Nephropathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Proteinuria, measured as Urine Protein to creatinine ratio (UPCR).
Renal function measured as estimated glomerular filtration rate (eGFR)
Secondary outcome measures
Renal function
The incidence of treatment-emergent adverse events.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NefeconExperimental Treatment1 Intervention
Nefecon 16 mg once daily by mouth for 9 months.
Group II: Placebo oral capsulePlacebo Group1 Intervention
Placebo oral capsule once daily by mouth for 9 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nefecon
2018
Completed Phase 3
~370
Find a Location
Who is running the clinical trial?
Calliditas Therapeutics ABLead Sponsor
9 Previous Clinical Trials
821 Total Patients Enrolled
Krassimir Mitchev, MDStudy DirectorCalliditas AB
1 Previous Clinical Trials
Share this study with friends
Copy Link
Messenger